Diabetes treatment is constantly advancing, with new therapeutic options appearing to improve patient outcomes. Recent studies have focused on GLP-1 and GIP receptor agonists, a category of drugs that mimic the actions of naturally occurring hormones involved in bloodlevel regulation. These novel agents demonstrate substantial efficacy in improving

Retaglutide and tirzepatide represent innovative type of medications glp known as dual GLP-1 and GIP agonists. These agents regulate both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), two hormones that play a crucial role in regulating blood sugar levels. In individuals with type 2 diabetes, these hormones